Recovery From COVID-19 in Multiple Sclerosis
A Prospective and Longitudinal Cohort Study of the United Kingdom Multiple Sclerosis Register

Afagh Garjani, MD, Rodden M. Middleton, MBA, Richard Nicholas, FRCP, and Nikos Evangelou, FRCP

Neurol Neuroimmunol Neuroinflamm 2022;9:e1118. doi:10.1212/NXI.0000000000001118

Abstract

Background and Objectives
To understand the course of recovery from coronavirus disease 2019 (COVID-19) among patients with multiple sclerosis (MS) and to determine its predictors, including patients’ pre–COVID-19 physical and mental health status.

Methods
This prospective and longitudinal cohort study recruited patients with MS who reported COVID-19 from March 17, 2020, to March 19, 2021, as part of the United Kingdom MS Register (UKMSR) COVID-19 study. Participants used online questionnaires to regularly update their COVID-19 symptoms, recovery status, and duration of symptoms for those who fully recovered. Questionnaires were date stamped for estimation of COVID-19 symptom duration for those who had not recovered at their last follow-up. The UKMSR holds demographic and up-to-date clinical data on participants as well as their web-based Expanded Disability Status Scale (web-EDSS) and Hospital Anxiety and Depression Scale (HADS) scores. The association between these factors and recovery from COVID-19 was assessed using multivariable Cox regression analysis.

Results
Of the 7,977 patients with MS who participated in the UKMSR COVID-19 study, 599 reported COVID-19 and prospectively updated their recovery status. Twenty-eight hospitalized participants were excluded. At least 165 participants (29.7%) had long-standing COVID-19 symptoms for ≥4 weeks and 69 (12.4%) for ≥12 weeks. Participants with pre–COVID-19 web-EDSS scores ≥7, participants with probable anxiety and/or depression (HADS scores ≥11) before COVID-19 onset, and women were less likely to report recovery from COVID-19.

Discussion
Patients with MS are affected by postacute sequelae of COVID-19. Preexisting severe neurologic impairment or mental health problems appear to increase this risk. These findings can have implications in tailoring their post–COVID-19 rehabilitation.
Many patients with multiple sclerosis (MS) evade the serious acute complications of coronavirus disease 2019 (COVID-19), such as hospitalization, respiratory failure, or death. Nevertheless, they may still have long-term effects of the infection, known as postacute sequelae of COVID-19 (PASC).

Understanding the burden of PASC among patients with MS and identifying its risk factors will inform MS rehabilitation services, which are going to deal with the emerging needs of patients with MS who had COVID-19. In this study, we aim to understand the course of recovery from COVID-19 in MS and to determine its predictors.

Methods

This prospective and longitudinal cohort study was conducted as part of the United Kingdom MS Register (UKMSR) COVID-19 study. Patients with MS had been reporting whether they had symptoms suggestive of COVID-19 and whether their diagnosis was confirmed by a health care provider or COVID-19 testing, from March 17, 2020—the start of the outbreak in the United Kingdom. Further information about COVID-19 testing was not collected, but, in the United Kingdom, patients with COVID-19 symptoms are only offered a PCR test. Mass COVID-19 testing in the United Kingdom was implemented on May 28, 2020—before then, PCR tests were only available to inpatients. All data were collected using online questionnaires.

Patients with MS with self-reported symptoms suggestive of COVID-19 were included in the study. They were followed up, by email reminders, every 2 weeks to update their COVID-19 symptoms and recovery status until reporting full recovery from COVID-19 symptoms (questions provided in eAppendix 1, links.lww.com/NXI/A670). Participants who reported full recovery also provided the duration of their COVID-19 symptoms. The submitted questionnaires were date stamped for estimation of COVID-19 onset were used.

The UKMSR holds demographic and up-to-date clinical data on registered patients, including comorbidities, MS type, date of MS diagnosis, disease-modifying therapies, web-based Expanded Disability Status Scale (web-EDSS) scores, and Hospital Anxiety and Depression Scale (HADS) scores. The most recent web-EDSS and HADS scores before COVID-19 onset were used.

Participants were grouped into 5 groups based on their web-EDSS score: (1) 0–2.5 (ambulatory without assistance and no or minimal neurologic impairment); (2) 3–3.5 (ambulatory without assistance and moderate neurologic impairment); (3) 4–5.5 (ambulatory without assistance and severe neurologic impairment); (4) 6–6.5 (ambulatory with assistance), and (5) ≥7 (restricted to wheelchair or bed).

HADS is scored (0–21) for anxiety and depression separately. Participants with HADS scores of ≥11 were considered as having probable anxiety or depression. Participants with anxiety, depression, or both were considered as 1 group because these conditions frequently coexist in MS, and the number of participants with anxiety or depression alone was small. Data collected until March 19, 2021, are presented according to STROBE guidelines.

Statistical Analysis

Data were analyzed using IBM SPSS Statistics for Windows, version 26 (IBM Corp., Armonk, NY; 2019).

Continuous variables with normal distribution are presented as mean (SD) and were compared using the independent samples t test. Continuous variables without normal distribution and ordinal variables are presented as median (interquartile range [IQR]) and were compared using the Mann-Whitney U test. The association between categorical variables was assessed using the χ² test or the Fisher exact test. The number of valid values for variables with missing data has been stated.

Univariable and multivariable Cox regression analyses, with time (days) from reporting COVID-19 to full recovery (event) as the dependent variable, were performed to assess the association between demographic and clinical variables and recovery from COVID-19. Participants with persistent symptoms at their last follow-up were censored. A directed acyclic graph was produced (eAppendix 2, links.lww.com/NXI/A670) to identify potential confounding factors, which were subsequently accounted for in the multivariable Cox regression analysis. This method avoids the introduction of bias in the analysis by the erroneous inclusion of colliders and mediators as confounding factors. Listwise deletion was implemented for missing data.
| Characteristic                        | <4 wk n = 371 | ≥4 wk n = 165 | ≥12 wk n = 69 |
|--------------------------------------|----------------|---------------|-------------|
| Age, mean (SD), y                    | 49 (11)        | 50 (11)       | 51 (11)     |
| Women, no. (%)                       | 275 (74.1)     | 136 (82.4) *  | 59 (85.5)*  |
| White ethnicity, no. (%)             | 350 (94.3)     | 157 (95.2)    | 68 (98.6)   |
| Comorbiditiesb, no. (%)              | n = 295        | n = 125       | n = 53      |
| Diabetes                             | 12 (4.1)       | 3 (2.4)       | 2 (3.8)     |
| Heart disease                        | 6 (2)          | 1 (0.8)       | 0 (0)       |
| Hyperlipidemia                       | 21 (7.1)       | 5 (4)         | 5 (9.4)     |
| Hypertension                         | 32 (10.8)      | 13 (10.4)     | 7 (13.2)    |
| Peripheral vascular disease          | 1 (0.3)        | 0 (0)         | 0 (0)       |
| Kidney disease                       | 3 (1)          | 3 (2.4)       | 0 (0)       |
| Liver disease                        | 1 (0.3)        | 0 (0)         | 0 (0)       |
| Lung disease                         | 30 (10.2)      | 18 (14.4)     | 10 (18.9)   |
| Anxiety and/or depressionc           | 80/252 (31.7)  | 57/113 (50.4) ** | 25/46 (54.3) * |
| Web-EDSS scoreb, median (IQR)        | 4 (2.625–6.5) n = 264 | 5 (3–6.5) n = 113 | 5.5 (4–6.5) *n = 50 |
| Web-EDSS score = 0–2.5, no. (%)      | 66 (25)        | 23 (20.4)     | 7 (14)      |
| Web-EDSS score = 3–3.5, no. (%)      | 45 (17)        | 11 (9.7)      | 4 (8)       |
| Web-EDSS score = 4–5.5, no. (%)      | 69 (26.1)      | 32 (28.3)     | 15 (30)     |
| Web-EDSS score = 6–6.5, no. (%)      | 53 (20.1)      | 31 (27.4)     | 15 (30)     |
| Web-EDSS score ≥7, no. (%)           | 31 (11.7)      | 16 (14.2)     | 9 (18)      |
| MS disease duration, median (IQR), y  | 10 (5–17) n = 359 | 11 (5.25–19) n = 160 | 13 (6.25–19) n = 68 |
| Type of MS, no. (%)                  |                |               |             |
| RRMS                                 | 265 (71.4)     | 114 (69.1)    | 48 (69.6)   |
| SPMS                                 | 65 (17.5)      | 33 (20)       | 15 (21.7)   |
| PPMS                                 | 24 (6.5)       | 10 (6.1)      | 5 (7.2)     |
| Unknown                              | 17 (4.6)       | 8 (4.8)       | 1 (1.4)     |
| Taking a DMT, no. (%)                | 188 (50.7)     | 84 (50.9)     | 32 (46.4)   |
| Alemtuzumab                          | 14 (3.8)       | 4 (2.4)       | 2 (2.9)     |
| Beta interferons                     | 31 (8.4)       | 5 (3)         | 2 (2.9)     |
| Cladribine                           | 8 (2.2)        | 3 (1.8)       | 0 (0)       |
| Dimethyl fumarate                    | 49 (13.2)      | 25 (15.2)     | 10 (14.5)   |
| Fingolimod                           | 22 (5.9)       | 11 (6.7)      | 3 (4.3)     |
| Glatiramer acetate                   | 16 (4.3)       | 12 (7.3)      | 7 (10.1)    |
| Natalizumab                          | 23 (6.2)       | 10 (6.1)      | 4 (5.8)     |
| Ocrelizumab                          | 15 (4)         | 8 (4.8)       | 3 (4.3)     |
| Rituximab                            | 0 (0)          | 2 (1.2)       | 1 (1.4)     |
| Siponimod                            | 1 (0.3)        | 0 (0)         | 0 (0)       |
| Teriflunomide                        | 8 (2.2)        | 3 (1.8)       | 0 (0)       |

Continued
Results are presented as adjusted hazard ratios with 95% confidence intervals.

Data Availability
Data are stored on the UKMSR Secure e-Research Platform at Swansea University Medical School. Line level data cannot be released, but qualified researchers, subject to governance, can request access to data.

Table 2 Results of the Multivariable Cox Regression Analysis\(^a\) of Pre–COVID-19 Factors Associated With Recovery From COVID-19

| Included in the analysis, no. | Censored, no. | aHR Lower 95% CI | Upper 95% CI | Adjustments |
|-------------------------------|----------------|-----------------|-------------|-------------|
| Age (1-y increment)           | 556            | 115             | 0.996       | 0.988       | 1.005        | None |
| Women vs men                  | 556            | 115             | **0.756**   | **0.609**   | **0.937**    | None |
| All other ethnicities vs White ethnicity | 556 | 115 | 1.374 | 0.937 | 2.016 | None |
| MS disease duration (1-y increment) | 538 | 112 | 0.995 | 0.983 | 1.008 | Age |
| Anxiety and/or depression\(^b,c\) | 314 | 65 | **0.708** | **0.533** | **0.941** | Age, Gender, Ethnicity, Web-EDSS categories |
| Web-EDSS\(^c\)               | 380            | 74              | —            | —           | —            | Age, Gender, MS disease duration, MS type |
| Score = 0–2.5 (reference)    | —              | —               | —            | —           | —            | —              |
| Score = 3–3.5                | —              | —               | 1.123        | 0.783       | 1.610        | —              |
| Score = 4–5.5                | —              | —               | 0.751        | 0.542       | 1.040        | —              |
| Score = 6–6.5                | —              | —               | 0.698        | 0.485       | 1.006        | —              |
| Score >7                     | —              | —               | **0.614**    | **0.381**   | **0.989**    | —              |
| MS type                      | 538            | 112             | —            | —           | —            | Age, Gender, MS disease duration |
| RRMS (reference)             | —              | —               | 1            | 1           | 1            | —              |
| SPMS                         | —              | —               | **1.049**    | **0.765**   | **1.438**    | —              |
| PPMS                         | —              | —               | **1.212**    | **0.798**   | **1.841**    | —              |
| Taking a DMT                 | 556            | 115             | 0.985        | 0.788       | 1.232        | Age, MS type |

Abbreviations: 95% CI = 95% confidence interval; aHR = adjusted hazard ratio; COVID-19 = coronavirus disease 2019; DMT = disease-modifying therapy; MS = multiple sclerosis; PPMS = primary progressive multiple sclerosis; RRMS = relapsing-remitting multiple sclerosis; SPMS = secondary progressive multiple sclerosis; Web-EDSS = web-based Expanded Disability Status Scale.

Bold indicates statistically significant findings.

\(^a\) Results of the univariable Cox Regression analysis are provided in eTable 2, links.lww.com/NXI/A670.

\(^b\) Participants with Hospital Anxiety and Depression Scale scores ≥11 for anxiety or depression were considered as having probable anxiety or depression, respectively.

\(^c\) Before COVID-19 onset.
participants (and all hospitalized nonparticipants) were admitted
to hospital because of COVID-19. Therefore, hospitalized pa-
tients with MS were excluded from the analysis. Participants did
differ in their baseline characteristics (including de-
mographics, MS type, web-EDSS score, disease-modifying
therapies, comorbidities, or having anxiety and/or
depression) from nonparticipants, except for a lower rate of
hypertension among participants (10.8%) than nonparticipants
(16.3%) (eTable 1, links.lww.com/NXI/A670).

Four hundred forty-four participants (77.8%) reported full
recovery from COVID-19 at their last follow-up. Their

---

**Figure** Frequency of COVID-19 Symptoms Among Patients With Multiple Sclerosis With Persistent Symptoms at Their Last Follow-up in ≥4 (A) and ≥12 (B) Weeks From Reporting COVID-19

### A. Reported COVID-19 symptoms at ≥4 weeks (n = 95)

| Symptom               | Prevalence (%) |
|-----------------------|----------------|
| Lower respiratory tract | (n = 46) |
| Gastrointestinal      | (n = 33)      |
| Change in smell or taste | (n = 28) |
| Upper respiratory tract | (n = 21) |
| Headache              | (n = 20)      |
| Fever                 | (n = 3)       |
| New muscle pain       | (n = 34)      |
| New or worse fatigue  | (n = 60)      |

### B. Reported COVID-19 symptoms at ≥12 weeks (n = 60)

| Symptom               | Prevalence (%) |
|-----------------------|----------------|
| Lower respiratory tract | (n = 35) |
| Gastrointestinal      | (n = 25)      |
| Change in smell or taste | (n = 17) |
| Upper respiratory tract | (n = 15) |
| Headache              | (n = 13)      |
| Fever                 | (n = 3)       |
| New muscle pain       | (n = 27)      |
| New or worse fatigue  | (n = 41)      |

Gastrointestinal symptoms included diarrhea, nausea or vomiting, or stomach pain. Lower respiratory tract symptoms included coughs, shortness of breath, or heaviness in the chest. Upper respiratory tract symptoms included sore throat, nasal congestion, or sneezing. COVID-19 = coronavirus disease 2019.
median (IQR) symptom duration was 10 (6–21) days (n = 441); 70 recovered in ≥4 weeks and 9 in ≥12 weeks. However, 127 participants (22.2%) had persistent symptoms at their last follow-up. They had been followed up for a median (IQR) of 87 (41–185) days (n = 115), with 95 having symptoms for ≥4 weeks and 60 for ≥12 weeks from reporting COVID-19. Therefore, at least 165 participants (29.7%) had lasting COVID-19 symptoms for ≥4 weeks and 69 (12.4%) for ≥12 weeks. The characteristics of participants by their symptom duration are compared in Table 1. A post hoc analysis among participants with a COVID-19 diagnosis confirmed by a health care provider or testing showed similar findings (eAppendix 3, links.lww.com/NXI/A670).

Participants with a pre–COVID-19 web-EDSS score of ≥7, participants with anxiety and/or depression before COVID-19 onset, and women were less likely to report recovery from COVID-19 (Table 2). Of 95 participants who reported their COVID-19 symptoms at ≥4 weeks, 78 (82.1%) had symptoms, which were not typical for MS (symptoms listed in Figure, except for fatigue and pain). Of 60 participants who reported their symptoms at ≥12 weeks, 50 (83.3%) had non–MS-related symptoms.

Discussion

This prospective study of a large national cohort of non-hospitalized patients with MS and COVID-19 shows that about 30% and 12% of patients experience prolonged COVID-19 symptoms for ≥4 and ≥12 weeks, respectively. These rates in the MS population are higher than the general population, as reported by a study using a similar methodology (13% and 2%, respectively).7 Another study reports a much higher prevalence of prolonged COVID-19 in the general population, but its retrospective data collection could have led to recall bias.8 Given that MS shares many neurologic symptoms of COVID-19 and that the infection can lead to MS exacerbations,9 a high prevalence of long-lasting COVID-19 symptoms in this population may seem expected. More than 80% of patients with MS with persistent COVID-19 symptoms in the study, however, also had symptoms that were not typical for MS. Further studies using direct control groups, from both the general population and patients with MS without COVID-19, are needed to establish the risk of PASC in MS.

An association between physical disability and adverse acute COVID-19 outcomes in MS has been previously reported.1 This study shows that higher levels of pre–COVID-19 neurologic disability predispose patients with MS to long-term sequelae of COVID-19 as well. Other MS-related factors such as disease duration or disease-modifying therapies did not appear to influence recovery from COVID-19. Patients with MS with pre–COVID-19 mental health problems can also be disproportionately affected by PASC, which has also recently been reported in the general population.10 The observation that women are more likely to experience prolonged COVID-19 symptoms is in accordance with other studies.

A limitation of the study is that the COVID-19 diagnosis of patients with MS was confirmed by laboratory testing in only a proportion of participants, as widespread testing was not available in the United Kingdom at the time of recruitment. However, the rates of prolonged COVID-19 in the subgroup with confirmed diagnosis and the total study population were similar. Hospitalized patients with MS were excluded to avoid the potential confounding effect of hospitalization on recovery from COVID-19. The association between hospitalization and COVID-19 recovery could not be assessed because of the small sample size of hospitalized patients with MS and the risk of selection bias toward nonhospitalized patients due to the questionnaire-based nature of the study.

These findings will inform MS and post–COVID-19 rehabilitation services in developing individualized pathways for patients with MS, helping to reduce the burden on these health systems in the COVID-19 era. They also highlight the importance of vaccination against COVID-19 in the MS population who appear to be vulnerable to the long-term effects of infection.

Study Funding

United Kingdom Multiple Sclerosis Society (Grant no. 131).

Disclosure

A. Garjani has received research support from the United Kingdom Multiple Sclerosis Society, speaker honorarium from the Multiple Sclerosis Academy, and travel support from Novartis, Merck, and the Multiple Sclerosis Academy. R.M. Middleton has received funding from the United Kingdom Multiple Sclerosis Society. R. Nicholas has received support for advisory boards and travel from Novartis, Roche, and Biogen. He has received grant support from the United Kingdom Multiple Sclerosis Society. He is a member of a National Institute for Health and Care Excellence (NICE) Health Technology Assessment (HTA) committee. N. Evangelou has served as a member of advisory boards for Biogen, Merck, Novartis, and Roche and has received grant income from the United Kingdom Multiple Sclerosis Society, Medical Research Council (MRC), Patient-Centered Outcomes Research Institute (PCORI), and National Institute for Health Research (NIHR). Go to Neurology.org/NN for full disclosures.

Publication History

Previously published in medRxiv: doi.org/10.1101/2021.06.25.21259256. Received by Neurology: Neuroimmunology & Neuroinflammation July 2, 2021. Accepted in final form October 7, 2021.
References

1. Salter A, Fox RJ, Newsome SD, et al. Outcomes and risk factors associated with SARS-CoV-2 infection in a North American Registry of patients with multiple sclerosis. JAMA Neurol. 2021;78(6):699-708.

2. Evangelou N, Garjani A, dasNair R, et al. Self-diagnosed COVID-19 in people with multiple sclerosis: a community-based cohort of the UK MS Register. J Neurol Neurosurg Psychiatry. 2020;92(1):107-109.

3. Marrie RA, Zhang L, Li X, et al. The validity and reliability of screening measures for depression and anxiety disorders in multiple sclerosis. Mult Scler Relat Disord. 2018;20:9-15.

4. Wood B, Van Der Mei IA, Ponsonby AL, et al. Prevalence and concurrence of anxiety, depression and fatigue over time in multiple sclerosis. Mult Scler. 2013;19(2):217-224.

5. von Elm E, Altman D, Egger M. On behalf of the Iniciativa STROBE. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med. 2007;147:573-577.

6. Williams TC, Bach CC, Matthiesen NB, Henriksen TB, Gagliardi L. Directed acyclic graphs: a tool for causal studies in paediatrics. Pediatr Res. 2018;84(4):487-493.

7. Sudre CH, Murray B, Varavsky T, et al. Attributes and predictors of long COVID. Nat Med. 2021;27(4):626-631.

8. Whitaker M, Elliott J, Chadeau-Hyam M, et al. Persistent Symptoms Following SARS-CoV-2 Infection in a Random Community Sample of 508,707 People [online]. Accessed July 1, 2021. hdl.handle.net/10044/1/89844.

9. Garjani A, Middleton RM, Hunter R, et al. COVID-19 is associated with new symptoms of multiple sclerosis that are prevented by disease modifying therapies. Mult Scler Relat Disord. 2021;52:102939.

10. Thompson EJ, Williams DM, Walker AJ, et al. Risk factors for long COVID: analyses of 10 longitudinal studies and electronic health records in the UK. medRxiv. 2021. 06.24.21259277; doi: https://doi.org/10.1101/2021.06.24.21259277

Appendix (continued)

| Name                  | Location                                                                 | Contribution                                                                 |
|-----------------------|--------------------------------------------------------------------------|------------------------------------------------------------------------------|
| Rodden M. Middleton, MBA | Population Data Science, Swansea University Medical School, Swansea, United Kingdom | Drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data; and study concept or design |
| Richard Nicholas, FRCP | Department of Cellular and Molecular Neuroscience, Imperial College London, London, United Kingdom | Drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data; study concept or design; and analysis or interpretation of data |
| Nikos Evangelou, FRCP  | Mental Health and Clinical Neurosciences Academic Unit, School of Medicine, University of Nottingham, Nottingham, United Kingdom; Clinical Neurology, Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom | Drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data; study concept or design; and analysis or interpretation of data |
